Your browser doesn't support javascript.
loading
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.
van den Berg, Joost H; Heemskerk, Bianca; van Rooij, Nienke; Gomez-Eerland, Raquel; Michels, Samira; van Zon, Maaike; de Boer, Renate; Bakker, Noor A M; Jorritsma-Smit, Annelies; van Buuren, Marit M; Kvistborg, Pia; Spits, Hergen; Schotte, Remko; Mallo, Henk; Karger, Matthias; van der Hage, Joris A; Wouters, Michel W J M; Pronk, Loes M; Geukes Foppen, Marnix H; Blank, Christian U; Beijnen, Jos H; Nuijen, Bastiaan; Schumacher, Ton N; Haanen, John B A G.
Afiliación
  • van den Berg JH; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Heemskerk B; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Rooij N; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Gomez-Eerland R; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Michels S; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Zon M; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Boer R; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Bakker NAM; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Jorritsma-Smit A; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Buuren MM; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Kvistborg P; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Spits H; AIMM Therapeutics, Amsterdam, The Netherlands.
  • Schotte R; Experimental Immunology, Amsterdam University Medical Centres, Amsterdam, Noord-Holland, The Netherlands.
  • Mallo H; AIMM Therapeutics, Amsterdam, The Netherlands.
  • Karger M; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van der Hage JA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Wouters MWJM; Department of Surgery, Leiden Universitair Medisch Centrum, Leiden, Zuid-Holland, The Netherlands.
  • Pronk LM; Surgical Oncology, Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, The Netherlands.
  • Geukes Foppen MH; Dutch Institute for Clinical Auditing, Leiden, The Netherlands.
  • Blank CU; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Beijnen JH; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Nuijen B; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, The Netherlands.
  • Schumacher TN; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Haanen JBAG; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University Department of Pharmaceutical Sciences, Utrecht, Utrecht, The Netherlands.
J Immunother Cancer ; 8(2)2020 08.
Article en En | MEDLINE | ID: mdl-32753545
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Linfocitos Infiltrantes de Tumor / Melanoma Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Linfocitos Infiltrantes de Tumor / Melanoma Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido